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Background HIV cohort collaborations, which pool data from diverse patient
cohorts, have provided key insights into outcomes of antiretroviral
therapy (ART). However, the extent of, and reasons for, between-
cohort heterogeneity in rates of AIDS and mortality are unclear.
Methods We obtained data on adult HIV-positive patients who started ART
from 1998 without a previous AIDS diagnosis from 17 cohorts in
North America and Europe. Patients were followed up from 1
month to 2 years after starting ART. We examined between-cohort
heterogeneity in crude and adjusted (age, sex, HIV transmission
risk, year, CD4 count and HIV-1 RNA at start of ART) rates of
AIDS and mortality using random-effects meta-analysis and
meta-regression.
Results During 61 520 person-years, 754/38 706 (1.9%) patients died and
1890 (4.9%) progressed to AIDS. Between-cohort variance in
mortality rates was reduced from 0.84 to 0.24 (0.73 to 0.28 for
AIDS rates) after adjustment for patient characteristics. Adjusted
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mortality rates were inversely associated with cohorts’ estimated
completeness of death ascertainment [excellent: 96–100%, good:
90–95%, average: 75–89%; mortality rate ratio 0.66 (95% confidence
interval 0.46–0.94) per category]. Mortality rate ratios comparing
Europe with North America were 0.42 (0.31–0.57) before and 0.47
(0.30–0.73) after adjusting for completeness of ascertainment.
Conclusions Heterogeneity between settings in outcomes of HIV treatment has
implications for collaborative analyses, policy and clinical care.
Estimated mortality rates may require adjustment for completeness
of ascertainment. Higher mortality rate in North American, com-
pared with European, cohorts was not fully explained by complete-
ness of ascertainment and may be because of the inclusion of more
socially marginalized patients with higher mortality risk.
Keywords HIV, AIDS, antiretroviral therapy, mortality, cohort, heterogeneity,
prognostic model, socio-economic status
Introduction
Results from collaborations of HIV cohort studies
have made important contributions to understanding
the use and effects of antiretroviral therapy (ART),
during the 16 years since it was introduced.1–8
Pooling data from a number of cohort studies leads
to increased power to estimate associations of prog-
nostic factors, such as CD4 cell count, HIV-1 RNA,
age, sex and transmission risk group with clinical out-
comes1 and to results that are generalizable to a range
of treatment contexts. However, applicability of re-
sults will be limited if event rates vary greatly be-
tween cohorts.
Between-cohort heterogeneity in event rates may
result from differences in patient characteristics and
differential outcomes of health care or study charac-
teristics, such as extent of loss to follow-up. However,
such heterogeneity has rarely been a focus of research
reports, which typically focus on overall trends. Here,
we analyse data from a large collaboration of HIV
cohort studies in Europe and North America to quan-
tify between-cohort heterogeneity in rates of clinical
events and death from initiation of ART. We investi-
gate the extent to which such heterogeneity is
explained by patient and cohort characteristics.
Methods
The ART Cohort Collaboration (ART-CC) is an inter-
national collaboration between the investigators of
cohort studies of HIV-1–positive patients from
Europe and North America. It was established in
2000 to estimate the prognosis of HIV-1 infected
treatment-naı¨ve patients initiating combination ART
and has been described in detail elsewhere.1,9
Prospective cohort studies were eligible for participa-
tion if they had enrolled at least 100 HIV-1–positive
patients aged 516 years, who had not previously
received antiretroviral treatment, started ART with a
combination of at least three antiretroviral drugs after
1996 and had a median duration of potential
follow-up of at least 1 year after ART initiation. All
cohorts provided anonymized data on a predefined set
of demographic, laboratory and clinical variables,
which were then pooled and analysed centrally. The
data set analysed here was assembled during 2010
and included data from the following 17 cohorts:
the AIDS Therapy Evaluation Project, Netherlands
(ATHENA),10 the Agence Nationale de la Recherche
sur le SIDA et les he´patites virales (ANRS) CO3 Aqui-
taine Cohort,11 the ANRS CO4 French Hospital Data-
base on HIV (FHDH),12 the EuroSIDA Study Group,13
the Italian Cohort of Antiretroviral-Naı¨ve Patients
(ICONA),14 the Ko¨ln/Bonn Cohort (CBC), Germany,15
the Proyecto para la Informatizacio´n del Seguimiento
Clı´nico-epidemiolo´gico de la Infeccio´n por HIV y SIDA
(PISCIS) Cohort,16 Cohorte de la Red de Investigacio´n
en Sida (CoRIS),17 the Royal Free Hospital Cohort,
UK,18 the HAART Observational Medical Evaluation
and Research (HOMER),19 British Columbia, Canada,
the South Alberta Clinic Cohort, Canada,20 the Swiss
HIV Cohort Study (SHCS),21 the 1917 Clinic Cohort
from the University of Alabama (UAB),22 the Veterans
Aging Cohort Study (VACS),23,24 the HIV Atlanta VA
Cohort Study (HAVACS),25 Vanderbilt-Meharry
Center for AIDS Research26 and the University of
Washington HIV Cohort, USA.27
All cohorts completed a survey of cohort characteris-
tics, including region covered, whether facilities were
community-based or hospital clinics, coverage of local
community, representativeness of ethnic groups, de-
privation levels and methods of following up patients
and ascertaining deaths. Cohorts also supplied infor-
mation on estimated completeness of ascertainment
of death, which was categorized as 1¼ excellent:
96–100%, 2¼ good: 90–95%, 3¼ average: 75–89%.
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At all sites, institutional review boards had approved
the collection of data.
Patients were eligible for inclusion in this analysis if
they started ART between January 1, 1998 and July 1,
2009, had measurements of CD4 count and HIV-1
RNA measured within 3 months before start of ART,
did not have an AIDS diagnosis before initiation of
ART and were not thought to have been infected with
HIV through injection drug use (IDU). IDU, who are
known to have worse prognosis, were excluded be-
cause the proportion of IDU varied between cohorts,
and our focus was on understanding between-cohort
differences among similar patients. Patients were fol-
lowed up for AIDS and all cause mortality between
31 days and 2 years after starting ART. Patients with
AIDS diagnoses or who died within 30 days of start-
ing ART were excluded, as early deaths and events
after the start of ART are not well recorded in all
cohorts. Patients not known to have died were con-
sidered lost to clinical follow-up at 3 months after
their last CD4 measurement, except when the last
measurement was within 6 months of the end of
study date. Data on follow-up were available up to
December 31, 2009.
Statistical methods
For each cohort, we used survival models based on
the exponential distribution (Poisson regression
models) to estimate crude and adjusted (for age,
sex, HIV transmission risk, year started ART, CD4
count and HIV-1 RNA measured within 3 months be-
fore start of ART) average rates of AIDS and mortality
between 31 days and 2 years after starting ART.
Adjusted rates were calculated from a model that
assumed similar covariate effects across cohorts and
cohort-specific baseline hazards and are reported for
the group of patients with the most frequently occur-
ring risk factor categories [baseline CD4 count
100–199 cells/mm3, log HIV-1 RNA 4–4.99 log
copies/ml, age 30–44 years, sex/risk group men who
have sex with men (MSM), calendar period of start-
ing ART (2000–03)]. We displayed heterogeneity
using forest plots and used random-effects
meta-analysis of log rate ratios to examine heterogen-
eity in crude and adjusted rates.28 The size of the
squares in the forest plots represents the weight
assigned to each study in the meta-analysis and is
proportional to the variance. Residual heterogeneity
was quantified as 2, the between-cohort variance in
the rate (estimated on the logarithmic scale using
the method of DerSimonian and Laird)29 and as the
estimated rate ratio comparing cohorts at the 10th
and 90th percentile of the distribution of the out-
come. We also calculated the I2 statistic,30 which is
the percentage of variation across studies that is be-
cause of heterogeneity rather than chance. We used
meta-regression to estimate associations with cohort
characteristics [completeness of death ascertainment
and region (Europe vs North America)] and the
proportion of heterogeneity explained by these
characteristics.
Sensitivity analyses
Two cohorts (HOMER and VACS) had a large propor-
tion of patients with unknown risk transmission
group, who may have been IDU. We, therefore, re-
peated analyses excluding ‘other’ risk group from all
cohorts. A survey found that 30% of those lost to
follow-up in FHDH had died.31 Therefore, we repeated
analyses randomly assigning the outcome dead to
30% of those lost to follow-up in the whole study
population. To see if non–AIDS-related deaths were
driving the differences in mortality rate, we repeated
analyses in those cohorts with cause of death avail-
able with AIDS-related death as the outcome.
All analyses were carried out using Stata version 11
(www.stata.com).
Results
Data were available on 38 706 patients enrolled in 17
HIV cohort studies. During 61 520 person-years of
follow-up, 754 (1.9%) patients died and 1890 (4.9%)
progressed to AIDS, of whom 245 died. Table 1 com-
pares characteristics of the cohorts and their included
patients. The number of patients contributing to this
analysis varied from 225 to 19 054 between cohorts,
and the proportion that died varied from <1% to
47%. The proportion of female patients ranged from
just <40% in FHDH to <3% in the two cohorts of US
veterans. The overall median age was 37 [inter-quar-
tile range (IQR): 31–45] years, but both the cohorts of
US veterans had a higher proportion of older patients:
the median age in VACS was 46 (38–53) years, and
10% were aged 460 years, compared with <5% in
the combined data set. After excluding the HOMER
and VACS cohorts, which had substantial number of
patients with unknown or ‘other’ transmission risk
group, 39% of patients were MSM with a range
across cohorts of 32–65%. The VACS cohort did not
report details of risk transmission group, although
those with known IDU or hepatitis C infection were
identified and excluded from the data set considered
here. Median CD4 cell count at start of ART was 250
cells/mm3, and varied between 200 and 292 cells/
mm3; the proportion of patients with severe immuno-
suppression (<25 cells/mm3) at start of ART varied
from <1% to 12%. Overall, 21, 38 and 41% of pa-
tients started ART during 1998–99, 2000–03 and
2004–08, respectively. Two cohorts contributed data
only on patients who started treatment in more
recent years: patients in UAB started ART after 2000
and in CoRIS after 2004.
Table 2 shows methods for ascertainment of deaths
and of following up patients who miss appointments,
based on the survey of cohort characteristics. Two co-
horts are based only in community clinics, 13 are
hospital-based and 2 recruit patients in hospitals
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and community treatment facilities. Of the 10
European cohorts, one is multinational, five are
national (with coverage ranging from 35 to 100%),
two are regional or provincial and two are based in
city university hospital clinics. The two Canadian co-
horts are provincial, with estimated 99% coverage in
the areas that they serve. The US cohorts are also
diverse: one regional, two associated with city univer-
sity hospital clinics and two including only veterans
who were previously in the US armed forces, one of
which is a city-based hospital and the other a na-
tional database.
In the Canadian cohorts, aboriginal people and
immigrants from sub-Saharan Africa are over-
represented compared with the general population in
the cohort catchment area. In the US veterans co-
horts, patients are mostly male, are on average older
than patients in other HIV cohorts and have higher
rates of alcohol and recreational drug use than in the
wider population. In another US cohort, UAB, Black
Americans are over-represented, whereas Latino and
Hispanic people are under-represented, and the
Washington cohort predominantly recruits White
MSM. Four of seven North American cohorts reported
substantial social deprivation (low income, unemploy-
ment and homelessness) among their patients. In
the European cohorts, sub-Saharan Africans were re-
ported to be over-represented in one cohort, but
under-represented in another.
Excluding the multinational EuroSIDA cohort, 6 of
the 16 cohorts claimed to be largely representative of
all HIV patients in their country. Ten cohorts link to
death registries, but the frequency of linkage varies
from every month to every 3 years. Self-assessed com-
pleteness of death ascertainment was higher in co-
horts from North America than from Europe. The
proportion of patients lost to clinical follow-up for
AIDS events by 2 years after the start of ART was
12%, but this varied across the cohorts from 2 to 21%.
Figure 1 shows that there was considerable between-
cohort heterogeneity in crude rates of AIDS and all
cause mortality. Between-cohort heterogeneity is quan-
tified in Table 3, which shows that the estimated mag-
nitudes of between-cohort variance (2¼ 0.73 for AIDS
and 0.84 for death) correspond to 8.9-fold differences
between crude rates of AIDS in cohorts at the 90th,
compared with the 10th percentile and 10.5-fold dif-
ferences in crude mortality rates. All P-values for
ATHENA
Aquitaine
CBC
CoRIS
EuroSIDA
FHDH
ICONA
PISCIS
Royal Free
SHCS
S. Alberta
HOMER
HAVACS
UAB
VACS
Vanderbilt
Washington
Cohort
21 (18–25)
16 (10–24)
32 (22–48)
25 (16–39)
12 (6–22)
25 (23–27)
14 (10–20)
19 (15–25)
27 (20–37)
15 (12–20)
33 (20–57)
12 (8–18)
29 (16–53)
87 (61–126)
112 (103–121)
54 (42–69)
39 (25–60)
person-years
Per 1000
  0.005 0.01 0.05 0.1 0.2
Tau-sq: 0.73
AIDS
ATHENA
Aquitaine
CBC
CoRIS
EuroSIDA
FHDH
ICONA
PISCIS
Royal Free
SHCS
S. Alberta
HOMER
HAVACS
UAB
VACS
Vanderbilt
Washington
Cohort
8 (6–10)
5 (3–11)
12 (6–22)
9 (4–18)
8 (4–17)
7 (6–8)
1 (0–4)
8 (6–13)
4 (2–9)
10 (7–14)
14 (6–30)
42 (34–51)
21 (10–41)
16 (7–36)
40 (35–46)
23 (16–33)
14 (7–29)
person-years
Per 1000
  0.001 0.01 0.03 0.06
Tau-sq: 0.84
Death
Figure 1 Crude rates (per 1000 person-years) of AIDS and all cause mortality by cohort, average rate estimated during the
period from 31 days to 2 years after start of ART. The size of the squares represents the weight assigned to each study in the
meta-analysis and is proportional to the number of events in that study (whiskers show 95% CI). 2 is the between-cohort
variance in the rate
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heterogeneity were < 0.001. Figure 2 shows that on
adjustment for patient characteristics between-cohort
heterogeneity was substantially attenuated from 0.73 to
0.28 for rates of AIDS and from 0.84 to 0.24 for mortality.
Adjusted cohort mortality rates were inversely asso-
ciated with completeness of ascertainment of death
(Figure 3): the ratio of mortality rates was 0.66
[95% confidence interval (CI) 0.46 to 0.94] per
decreasing category of completeness. The between-
cohort heterogeneity variance in adjusted mortality
rates was further reduced from 0.28 to 0.11 (ratio
comparing 90th to 10th percentile 2.34) after adjust-
ment for completeness of death ascertainment. The
adjusted mortality rate ratios comparing European
with North American cohorts were 0.42 (95% CI
0.31–0.57) before and 0.47 (0.30–0.73) after adjusting
for completeness of ascertainment.
Results of sensitivity analyses
Risk group was ‘other’ in 20% of all patients, with a
cohort range of 1–78% (HOMER) and 100% (VACS).
The mortality hazard ratio for comparing ‘other’
with MSM varied by cohort, e.g. it was 1.38 (95%
CI 0.91–2.09) in FHDH, but 6.16 (2.24–16.90) in
HOMER. In analyses restricted to individuals with
transmission risk group recorded either as MSM or
heterosexual (16 cohorts n¼ 31 068 patients), the
between-cohort variance in crude mortality rates
was 0.16 (0.15 for AIDS rates), substantially lower
than those in the main analyses (Table 3 and Supple-
mentary Figure S1, available as Supplementary data at
IJE online). After adjustment for patient characteristics
at start of ART, these reduced further to 0.13 and 0.12
for mortality and for AIDS, respectively (Table 3 and
Supplementary Figure S2, available as Supplementary
data at IJE online). In the analysis that assumed 30% of
those lost to follow-up were dead, between-cohort vari-
ance in crude mortality rates was 0.19 compared with
0.84 in the main analysis (Table 3 and Supplementary
Figure S3, available as Supplementary data at IJE
online). In analyses restricted to 14 cohorts with cause
of death data available, between-cohort variance was
0.83 for AIDS-related deaths compared with 0.64 for
all cause mortality.
Discussion
In analyses of data pooled from 17 cohorts of
HIV-positive patients treated with ART from Europe
and North America, substantial between-cohort het-
erogeneity in crude rates of AIDS and death from
1 month to 2 years after starting ART was reduced
Table 3 Between-cohort heterogeneity in crude and adjusted rates of AIDS and mortality for (i) all patients; (ii) for MSM
and heterosexual transmission risk groups only; and (iii) for all patients, assuming 30% of those lost to follow-up are dead
Estimate
Between-cohort
heterogeneity
statistica s2
Rate ratio comparing
cohorts at the 10th
and 90th percentiles
of the distribution of
the outcome
Percentage of
variation across
studies because
of heterogeneity, I2
All patients
Rate of AIDS
Crude 0.73 8.93 98.5
Adjusted 0.28 3.88 94.4
Mortality rate
Crude 0.84 10.48 97.0
Adjusted 0.24 3.51 86.0
MSM and heterosexual onlyb
Rate of AIDS
Crude 0.15 2.70 88.0
Adjusted 0.12 2.43 84.6
Mortality rate
Crude 0.16 2.79 74.2
Adjusted 0.13 2.52 67.6
All patients, adjusted for loss to follow-up
Mortality rate
Crude 0.19 3.06 94.8
Adjusted 0.15 2.70 92.2
a2 is the estimated variance of the distribution of the rate of AIDS or rate of death among the cohorts.
bExcluding VACS.
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S. Alberta
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Washington
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17 (15–20)
15 (10–22)
28 (19–42)
23 (15–36)
10 (5–18)
22 (21–24)
13 (9–18)
15 (11–19)
21 (15–28)
12 (10–16)
31 (19–53)
8 (5–12)
20 (11–37)
68 (47–99)
72 (59–86)
34 (27–44)
30 (19–47)
person-years
Per 1000
  0.005 0.01 0.05 0.1 0.2
Tau-sq: 0.28
AIDS
ATHENA
Aquitaine
CBC
CoRIS
EuroSIDA
FHDH
ICONA
PISCIS
Royal Free
SHCS
S. Alberta
HOMER
HAVACS
UAB
VACS
Vanderbilt
Washington
Cohort
6 (5–8)
5 (2–9)
9 (5–17)
7 (3–15)
7 (3–14)
6 (5–7)
1 (0–3)
6 (4–10)
3 (2–8)
8 (6–11)
12 (5–27)
19 (15–25)
10 (5–20)
11 (5–25)
13 (10–16)
15 (10–22)
12 (6–25)
person-years
Per 1000
  0.001 0.01 0.03 0.06
Tau-sq: 0.24
Death
Figure 2 Adjusted rates (per 1000 person-years) of AIDS and all cause mortality by cohort, average rate estimated during
the period from 30 days to 2 years after start of ART. Adjusted for CD4 cell count (100–199) cells/mm3, log HIV-1 RNA
(4–4.99) log copies/ml, age (30–44 years), sex-risk group (MSM), year of starting ART (2000–03)
1
2
5
10
20
M
or
ta
lit
y 
ra
te
 
pe
r 
10
00
 
py
rs
 (lo
g s
ca
le
)
96-100% 90-95% 75-89%
Completeness of death ascertainment
Figure 3 Association of cohort-specific death rate (adjusted for patient characteristics) with ascertainment of death cat-
egory. Circle sizes represent the precision of each cohort-specific estimate (the inverse of within-cohort variance), yellow
denotes Canadian, blue USA and green European cohorts. 2 ¼ 0.11 (from 0.84)
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after adjustment for patient characteristics at base-
line. However, even after adjustment, there were
3.88- and 3.51-fold differences for AIDS and death,
respectively, comparing cohorts at the 90th and 10th
percentiles of the distribution of rates. Cohort-specific
mortality rates were inversely associated with
self-assessed completeness of death ascertainment.
Therefore, mortality rates estimated from different
HIV cohort studies may require adjustment for com-
pleteness of death ascertainment especially, if loss to
follow-up is high. Higher mortality rates in North
American, compared with European, cohorts were
not fully explained by completeness of ascertainment.
However, much of the heterogeneity seemed to be
attributable to higher death rates in patients with ‘un-
known’ risk transmission group in the HOMER and
VACS cohorts who are likely to be from more socially
marginalized groups.
Strengths and limitations
Our study includes 40 000 patients enrolled in 17
diverse cohorts from two continents. None of the co-
horts in ART-CC estimated self-assessed death ascer-
tainment to be <75%; the effect of more extreme
levels of under-ascertainment on estimated rates of
AIDS and death is unpredictable. We excluded pa-
tients whose presumed transmission was through
IDU or who had experienced AIDS before starting
ART to reduce the influence of pre-existing conditions
and co-morbidities in increasing between-cohort het-
erogeneity. Similarly, we focused on the first 2 years
of treatment to reduce the impact of treatment
switches or failure, and started follow-up after 1
month, because early events may not be completely
recorded in some cohorts. Completeness of death as-
certainment was self-assessed by cohorts. Although
some cohorts have good empirical evidence to support
such assessments,31 true completeness remains un-
known. Some demographic and clinical variables
that might contribute to between-cohort heterogen-
eity were not available to us, e.g. we did not have
complete patient-level data on country of origin and
race, nor did we have information on viral subtype,
education or socio-economic status. Our analyses did
not account for non-HIV biomarkers that have been
shown to be associated with mortality rate in treated
HIV-positive patients, such as haemoglobin,32 liver
enzymes and creatinine,33 because these measures
were not available from all cohorts. We were also
unable to adjust for important lifestyle risk factors
for all cause mortality, such as smoking, alcohol and
drug use.
Results in context with other studies
A study that used a prognostic model fitted to data
from the Collaborations in HIV Outcomes
Research/US cohort to predict AIDS free survival in
the Johns Hopkins HIV Clinical Cohort found consid-
erable discrepancies between predicted and observed
survival.34 This was only partially explained by mea-
sured risk factors and may have been partly because
of substantial differences in loss to follow-up rates.
There were clear differences in mortality rates
during the first year of ART when data from this col-
laboration of cohorts from high-income countries
were compared with those from a collaboration of
ART treatment programmes in low-income countries.6
Such differences are likely to reflect the greater
burden of background disease, poorer access to ART
leading to lower CD4 counts at start of ART,
sub-optimal ART regimens and lack of health care
infrastructure in the low-income countries. That
study also found estimated mortality rates to be sub-
stantially higher, and estimated rates of loss to
follow-up correspondingly lower, in cohorts with
active compared with passive follow-up.
Contributors to between-cohort
heterogeneity
The differences in mortality rates between cohorts in
our study may be attributable to under-ascertainment
of mortality, loss to follow-up related to prognosis or
to patients having higher mortality risk beyond that
due to the characteristics accounted for in the ana-
lysis. We found evidence that mortality rates were
related to completeness of death ascertainment,
which varied by cohort and depended on factors
such as linkage to registries, the existence of good
subject identifiers, such as National Insurance num-
bers, and the proportion of migrants.35 Under-
ascertainment of death was found in France when
they conducted a national survey of mortality rate
in HIV-positive individuals during 2000 using three
source capture–recapture methods, which found that
only 38% of deaths of persons in the FHDH had been
recorded and that under-ascertainment was more
common for non-AIDS compared with AIDS-related
deaths.31 The mortality survey was repeated in
200536 ensuring more complete ascertainment of
death in the data contributed to the present study.
Frequent linkage with death registries is essential
for the accurate estimation of mortality rate.37,38
We also found that rates of loss to follow-up varied
by cohort from 2 to 18% and depend on the opportu-
nities to access care outside the contributing centres,
the ability of cohorts to track patient transfers and
methods of chasing patients who miss appointments.
Prognosis associated with loss to follow-up could bias
estimates of mortality rates. In France, IDU and im-
migrants were more likely to be lost to follow-up and,
compared with those remaining in care, CD4 count
was lower and viral load higher,34 whereas in
Switzerland those lost to follow-up had higher CD4
count.39 Patients lost to follow-up from cohort
studies could remain in care in non-contributing in-
stitutions, such as primary care facilities, and also
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often return to care in the contributing institutions
after a gap of over 1 year.38,40 Service delivery is a
key factor that needs to be considered; among the
population-based cohorts, several are solely respon-
sible for providing antiretroviral care for these partici-
pants; therefore, they are less likely than clinic-based
cohorts to lose participants because of transfer of care
to other facilities or to under-reported mortality. For
example, the high rates of loss to follow-up in the
Royal Free cohort are partly because of patients at-
tending multiple clinics in London.38
Methods of adjustment for
under-ascertainment of deaths
Standard methods of survival analysis assume that
censoring is uninformative, i.e. that study participants
who are censored because they are lost to follow-up
have similar mortality rates compared with those that
remain in the study, conditional on their observed
covariates. This is not the case in resource-limited
settings; a systematic review of studies that traced
patients lost to follow-up found that among those
traced, 20–60% had died, a much higher mortality
rate than that recorded for those remaining in
care.41 Mortality rate in those lost to follow-up but
later traced was inversely associated with the rate of
loss to follow-up in the programme. Loss to follow-up
may be treated as a missing data problem and miss-
ing survival time imputed accounting for covariate
pattern and the excess mortality ratio in those lost
to follow-up.42 Often, the cohort-specific excess mor-
tality ratio is not known, but may be estimated from
other studies or a range of plausible values used to
explore sensitivity of overall mortality to this ratio.43
Future work will use similar methods to explore ad-
justments for under-estimation of mortality in
European and North American cohorts.
Possible reasons for higher death rates in
USA and Canada
We found that mortality rates were substantially
higher in two North American cohorts (HOMER and
VACS) and that this was largely attributable to pa-
tients with unknown transmission risk group, who
are likely to be more socially marginalized. Based on
discussion with representatives from the cohort, it is
likely that in HOMER, some patients infected through
IDU and likely to be co-infected with hepatitis C were
classified as ‘other’ and should have been excluded
from these analyses. Some variations in mortality pat-
terns seen in our study can be attributed to the dif-
ferences between population-based and clinic-based
cohorts. Because of patient profiles and expertise,
clinic-based cohorts may self-select for certain types
mf participants, whereas population-based cohorts are
more representative and, therefore, may include
people who are more disadvantaged and with higher
risk for death. Mortality rates may also be affected by
staffing numbers, physician experience, active
engagement of patients through social workers and
active tracing of patients that miss appointments.
Rates of deaths unrelated to HIV may be greater in
some North American cohorts, particularly those be-
cause of suicide, homicide, drug and alcohol overdose
and accidents. Higher rates of co-infection with hepa-
titis B or C may also lead to worse mortality.
Canadian and veterans cohorts in USA contributing
to ART-CC have a high prevalence of drug use and
alcohol misuse.44,45 Life expectancy varies between46
and within countries; compared with Whites, it is
lower for Blacks in USA47 and for Aboriginal peoples
in Canada44,48, and there are a sizable proportion of
these groups in North American ART-CC cohorts.
Despite the provision of free universal health care in
Canada, neighbourhood measures of socio-economic
status (percentage of residents below the poverty
line) and lower educational attainment were asso-
ciated with higher mortality on ART;49 migration
(change of address) during ART was common and
adversely affected adherence to ART50 and housing
status predicted disease progression.51 Housing stabil-
ity may vary considerably between cohorts in ART-CC
but is not directly captured, although it is likely to
contribute to variation in loss to follow-up rates.
Implications and conclusion
Our research suggests the need for linkage to death
registries to reduce under-ascertainment of death.
There is also a need for linkage of patient records
between clinics to reduce loss to follow-up when
care is transferred to another site. Comparative ana-
lyses of mortality in HIV-positive individuals from di-
verse geographical and socio-economic settings should
include sensitivity analyses that adjust for under-
ascertainment of death and loss to follow-up.
However, methods of adjustment are not straightfor-
ward, and interpretation of results may be prob-
lematical. Prognostic models and estimates of life
expectancy that use pooled data from collaborations
of cohorts should account for the between-cohort
variation in mortality rates. In the same way that
the Framingham equation for cardiovascular disease
has been recalibrated for populations with different
mortality rates,52 prognostic models for HIV progres-
sion will also need to be calibrated for different popu-
lations of patients. An exploration of the drivers of
the higher mortality in some of the HIV cohorts con-
tributing data to ART-CC would require collection of
detailed data on socio-economic variables and lifestyle
risk factors and consideration of mortality in matched
HIV-negative persons. As the proportion of deaths
that are not AIDS-related increases, mortality patterns
in HIV-positive individuals are increasingly likely to
reflect social disadvantage, which will vary between
and within cohorts. Targeting health resources to the
most disadvantaged groups might decrease disparities
in outcomes. We will be addressing these issues in
future analyses that use data from ART-CC.
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KEY MESSAGES
 There were significant differences in rates of AIDS and death in cohorts of HIV patients treated with
ART in Europe and North America.
 The between-cohort variance in mortality rates was reduced by a substantial amount after adjustment
for patient characteristics.
 Some of the residual between-cohort heterogeneity can be explained by under-ascertainment of deaths.
 Mortality rates estimated from different HIV cohort studies may require adjustment for completeness
of death ascertainment, especially if loss to follow-up is high.
 Higher mortality rates in North American, compared with European, cohorts may be because of the
inclusion of more socially marginalized patients with higher mortality risk.
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